Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Institute of Clinical Medicine, Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan.
Circ Arrhythm Electrophysiol. 2012 Jun 1;5(3):514-20. doi: 10.1161/CIRCEP.111.968032. Epub 2012 May 1.
Catheter ablation of atrial fibrillation (AF) became an effective therapy for patients with drug-refractory AF, and the indications have broadened to include nonparoxysmal AF patients. However, data about the long-term effectiveness of ablation in patients with nonparoxysmal AF are lacking. The aim of the present study was to investigate the long-term outcomes of catheter ablation in patients with nonparoxysmal AF.
A total of 88 nonparoxysmal AF patients who received a stepwise catheter ablation (isolation of the pulmonary veins plus substrate modification) from 2006 to 2008 were enrolled. Freedom of recurrence was defined as the absence of atrial arrhythmias without using any antiarrhythmic agents after the catheter ablation. There were 63 patients (71.6%) with recurrences (47 patients with AF and 16 patients with atrial flutter/atrial tachycardia) after the initial procedure during a median follow-up period of 36.8 months. A CHADS2 score of ≥3 and the left atrial (LA) diameter were significant predictors of recurrences in the multivariable analysis. Of the patients with CHADS2 scores of ≥3 and an LA dimension≥44 mm, all had recurrences within 1 year after the initial procedure. The overall recurrence-free rate could increase to 47.7% after the second procedure and 51.1% after the third procedure.
The long-term recurrence-free rate of ablation in nonparoxysmal AF was only 28.4% after a single procedure, and multiple procedures were necessary to raise the recurrence-free rate. The CHADS2 score and LA dimension may help us to identify patients who will have recurrences after catheter ablations of nonparoxysmal AF.
导管消融术已成为药物难治性房颤患者的有效治疗方法,适应证已扩大至包括非阵发性房颤患者。然而,对于非阵发性房颤患者消融治疗的长期疗效数据尚缺乏。本研究旨在探讨导管消融术治疗非阵发性房颤的长期疗效。
共纳入 88 例 2006 年至 2008 年接受阶梯式导管消融(肺静脉隔离加基质改良)的非阵发性房颤患者。消融后无房性心律失常且未使用任何抗心律失常药物定义为无复发。在中位随访 36.8 个月时,初始消融后有 63 例(71.6%)患者(47 例为房颤,16 例为房扑/房速)复发。多变量分析显示,CHADS2 评分≥3 分和左心房(LA)直径是复发的显著预测因素。在 CHADS2 评分≥3 分且 LA 内径≥44mm 的患者中,所有患者在初始消融后 1 年内均复发。第二次消融后总体无复发率可增加至 47.7%,第三次消融后可增加至 51.1%。
单次消融治疗非阵发性房颤的无复发率仅为 28.4%,需要多次消融才能提高无复发率。CHADS2 评分和 LA 内径有助于预测非阵发性房颤患者消融后复发的可能性。